Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Solvay Pharmaceuticals
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00553059
First received: November 2, 2007
Last updated: February 11, 2014
Last verified: February 2014

November 2, 2007
February 11, 2014
October 2007
March 2015   (final data collection date for primary outcome measure)
Number of Participants with Total protection [ Time Frame: 5 Days (first 5 days of the first cycle of chemotherapy) ] [ Designated as safety issue: No ]
Total protection is defined as no vomiting, no rescue therapy, and no nausea as indicated by responses to the Daily Assessment of Nausea and Vomiting questionnaire during the overall [0-120 hour] period.
Total protection (i.e., no vomiting, no rescue therapy, and no nausea as indicated by responses to the Daily Assessment of Nausea and Vomiting questionnaire during the overall [0-120 hour] period)
Complete list of historical versions of study NCT00553059 on ClinicalTrials.gov Archive Site
  • Acute, Delayed and Overall Total Protection [ Time Frame: Up to 5 days (first 5 days of the first cycle of chemotherapy) ] [ Designated as safety issue: No ]
    Total protection is defined as no vomiting, no rescue therapy, and no nausea evaluated for the acute (0-24 hour), delayed (24-120 hour), and overall (0-120 hour) periods as indicated by responses to the Daily Assessment of Nausea and Vomiting questionnaire.
  • Complete response and Complete Protection for the acute, delayed, and overall periods [ Time Frame: Up to 5 days (first 5 days following first cycle of chemotherapy) ] [ Designated as safety issue: No ]
    Complete response is defined as vomiting episodes with rescue medication, and Complete Protection is no vomiting, no rescue therapy, and no nausea evaluated for the acute (0-24 hour), delayed (24-120 hour), and overall (0-120 hour) periods as indicated by responses to the Daily Assessment of Nausea and Vomiting questionnaire.
  • No vomiting, no significant nausea, and no nausea evaluated for the acute (0-24 hour), delayed (24-120 hour), and overall (0-120 hour) periods
  • Complete protection and complete response for the acute, delayed, and overall periods
Not Provided
Not Provided
 
Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer
Randomized, Double-Blind, Placebo-Controlled Trial of Palonosetron/Dexamethasone With or Without Dronabinol for the Prevention of Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy

The goal of this clinical research study is to learn if adding dronabinol in combination with the standard of care (dexamethasone and palonosetron) can better help to control nausea and vomiting in patients receiving chemotherapy. The safety of the drug combinations will also be studied.

The Study Drugs:

Dronabinol and palonosetron are both designed to help prevent nausea and vomiting in patients who are receiving chemotherapy.

Dexamethasone is a corticosteroid that is similar to a natural hormone made by your body. Dexamethasone is often given to MM patients in combination with other chemotherapy to treat cancer.

Study Groups:

If you are found to be eligible to take part in this study, you will be randomly assigned (as in the flip of a coin) to 1 of 2 groups.

  • If you are in Group 1, you will take dronabinol, dexamethasone, and palonosetron.
  • If you are in Group 2, you will take a placebo, dexamethasone, and palonosetron. A placebo is a substance that looks like the study drug but has no active ingredients.

You will have an equal chance of being assigned to either group. Neither you nor your doctor can choose the group you will be in. During the study, you and the study staff will not know which group you are in. However, if needed for your safety, the study staff will be able to find out which group you are in.

After the last study participant completes their study therapy, you and the study staff will find out which group you were in.

Study Drug Administration:

On Day 1 (the day that you receive chemotherapy), you will take a dronabinol/placebo pill by mouth every 8 hours (if possible). If you cannot take the pill every 8 hours, you should try to space out the doses evenly. Your first dronabinol/placebo pill on Day 1 will be 30 minutes before chemotherapy.

You will also receive dexamethasone and palonosetron by vein 30 minutes before you receive chemotherapy.

On Days 2-6, you will take dronabinol/placebo 3 times a day. You should take each pill every 8 hours (if possible). If you cannot take them every 8 hours, you should try to space out the doses evenly.

Study Diary:

You will complete a study diary on Days 1-6. In this diary you will answer questions about nausea and vomiting.

Study Visits:

You will have a study visit on Day 8 and again sometime during Days 14-28. At both visits, you will be asked if you have experienced any side effects. You should return your study diary to the clinic at both visits. At the visit during Days 14-28, you will also have a physical exam.

Length of Study:

You will be on study for 30 days. You will be taken off study early if the nausea and vomiting do not improve or intolerable side effects occur.

This is an investigational study. Dronabinol and palonosetron are both FDA approved and commercially available to prevent nausea and vomiting that may occur from chemotherapy. Dexamethasone is FDA approved and commercially available for the prevention of side effects related to chemotherapy. The combination of these drugs to prevent nausea and vomiting is investigational.

Up to 200 patients will take part in this multicenter study. Up to 200 will be enrolled at M. D. Anderson.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Supportive Care
  • Chemotherapy-induced Nausea and Vomiting
  • Unspecified Adult Solid Tumor, Protocol Specific
  • Drug: dexamethasone
    10 mg IV 30 minutes prior to administration of chemotherapy
  • Drug: dronabinol
    5 mg tablet by mouth three times a day beginning 30 minutes before chemotherapy
  • Drug: palonosetron hydrochloride
    0.25 mg IV 30 minutes prior to administration of chemotherapy
  • Other: placebo
    1 tablet by mouth three times a day beginning 30 minutes before chemotherapy
  • Experimental: Arm I: Palonosetron, Dexamethasone + Dronabinol
    Palonosetron hydrochloride intravenous (IV) and dexamethasone IV 30 minutes before chemotherapy administration on day 1, and oral dronabinol 3 times a day for 5 days beginning 30 minutes before chemotherapy administration on day 1.
    Interventions:
    • Drug: dexamethasone
    • Drug: dronabinol
    • Drug: palonosetron hydrochloride
  • Active Comparator: Arm II: Palonosetron + Dexamethasone
    Palonosetron hydrochloride and dexamethasone as in arm I, and oral placebo 3 times a day for 5 days beginning 30 minutes before chemotherapy on day 1.
    Interventions:
    • Drug: dexamethasone
    • Drug: palonosetron hydrochloride
    • Other: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
200
Not Provided
March 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Histologically or cytologically documented solid tumor
  2. Receiving moderately emetogenic chemotherapy for the first time: Patients may be chemotherapy naive, or patients may have previously received a mildly emetogenic agent (such as a taxane) if no nausea/vomiting was experienced with that chemotherapy
  3. Scheduled to receive cyclophosphamide </= 1500 mg/m^2 IV and/or doxorubicin >/= 40 mg/m^2 IV given as single doses on Day 1. Patients on combination regimens with these agents are eligible
  4. Age >/= 18 years
  5. ECOG Performance Status 0-2
  6. Adequate organ reserve as follows: 1) Hematologic - WBC >/= 3000/microL, AGC >/= 1500/microL, platelet >/= 100,000/microL; 2) Renal - Creatinine </= 1.5 times upper limit of normal; 3) Hepatic - Bilirubin and transaminases </= 2.5 times upper limit of normal
  7. The effects of the three-drug regimen on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  8. Negative qualitative B-HCG (pregnancy test)
  9. Signed informed consent

Exclusion Criteria:

  1. Scheduled to receive highly emetogenic chemotherapy (Hesketh Level 5 - such as cisplatin, streptozotocin, dacarbazine, carmustine, hexamethylmelamine, mechlorethamine, procarbazine) during the study period
  2. Scheduled to receive moderately emetogenic chemotherapy (Hesketh Level 3-4) after Day 1 of the study period
  3. Experienced nausea and/or vomiting with prior administration of chemotherapy
  4. Prior moderately or highly emetogenic chemotherapy: Patients may have previously received a mildly emetogenic agent (such as a taxane) if no nausea/vomiting was experienced with that chemotherapy
  5. Scheduled to receive cranial, abdominal, or pelvic radiation therapy during the study period
  6. Treatment with any investigational agent within 30 days of randomization
  7. Scheduled to receive treatment during the study period with other potential or known antiemetic agents. Chronically used benzodiazepines may be continued as a single nightly dose for sleep.
  8. Scheduled to receive corticosteroid treatment other than the study drug dose during the study period
  9. Uncontrolled primary or metastatic CNS tumor (including those with uncontrolled seizures)
  10. Other physical causes for nausea or vomiting (such as bowel obstruction) not related to chemotherapy administration
  11. Recent history of unexplained nausea or vomiting or history of frequent nausea or vomiting
  12. Active bacterial or fungal infection for which administration of a corticosteroid would be contraindicated
  13. Hypersensitivity to any of the study agents
  14. Sensitivity to sesame oil
  15. Planned simultaneous administration of any other investigational agents
  16. Pregnant or nursing women
  17. Previous poor tolerance of cannabinoids
  18. Habitual cannabinoid use or unwillingness to avoid the use of marijuana during the study period
  19. Previous use of dronabinol or nabilone
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00553059
2006-0841, MDA-2006-0841, CDR0000573510, NCI-2009-00637
Yes
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
  • Solvay Pharmaceuticals
Study Chair: Steven M. Grunberg, MD University of Vermont
Study Chair: Amal I. Melhem-Bertrandt, MD M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP